| 1 |
35053380 | Phosphorylation-Induced Ubiquitination and Degradation of PXR through CDK2-TRIM21 Axis. | 2022 Jan 13 |
1 |
| 2 |
34688130 | Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia. | 2021 Dec |
2 |
| 3 |
31529315 | Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells. | 2020 Apr |
1 |
| 4 |
32368395 | Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma. | 2020 |
2 |
| 5 |
32395375 | Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers. | 2020 Apr |
1 |
| 6 |
32433863 | Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2. | 2020 Jul 17 |
2 |
| 7 |
33050377 | Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer. | 2020 Oct 10 |
1 |
| 8 |
33116269 | Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. | 2020 Oct 28 |
1 |
| 9 |
31439587 | PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. | 2019 Nov 15 |
1 |
| 10 |
29507054 | Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors. | 2018 Mar 5 |
2 |
| 11 |
28107181 | Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. | 2017 Feb 28 |
1 |
| 12 |
28249908 | Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. | 2017 May 1 |
1 |
| 13 |
28947566 | Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. | 2017 Dec 1 |
2 |
| 14 |
29137354 | ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition. | 2017 Oct 13 |
1 |
| 15 |
27378523 | Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. | 2016 Jul 5 |
4 |
| 16 |
27550941 | Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2. | 2016 Nov |
1 |
| 17 |
25395429 | Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. | 2015 Jan 15 |
1 |
| 18 |
25947565 | A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. | 2015 Aug |
1 |
| 19 |
25962959 | Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. | 2015 Jun 20 |
1 |
| 20 |
25217392 | Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. | 2014 Nov |
1 |
| 21 |
24007471 | Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. | 2013 Nov 15 |
2 |
| 22 |
23053255 | Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. | 2012 Dec |
1 |